Effects of L-Arginine and Liposomal Vitamin C on Physical Performance in Older Adults

Effects of L-arginine and Liposomal Vitamin C Supplementation on Physical Performance and Endothelial Function in Elderly With Sarcopenia

This study is testing whether taking L-arginine and liposomal vitamin C can help older adults with muscle loss feel stronger and less tired.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 70 Years and up
• Sex: All
• Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS (other)
• Locations: 1 site (Roma)
• Trial ID: NCT06865261 on ClinicalTrials.gov

What this trial studies

This study investigates the impact of L-arginine and liposomal vitamin C supplementation on physical performance in older adults suffering from sarcopenia, a condition characterized by muscle loss and weakness. The trial aims to determine whether these supplements can enhance physical function and reduce fatigue, potentially improving the quality of life for participants. By focusing on older adults, the study addresses a critical health issue associated with aging and mobility. Participants will be randomly assigned to receive either the active supplements or a placebo to evaluate the effectiveness of the intervention.

Who should consider this trial

Good fit: Ideal candidates for this study are older adults diagnosed with probable sarcopenia according to EWGSOP2 criteria.

Not a fit: Patients with severe comorbidities, cognitive impairments, or those residing in nursing homes may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a novel non-pharmacological approach to improve physical performance and quality of life in older adults with sarcopenia.

How similar studies have performed: While there is emerging evidence supporting the benefits of L-arginine and vitamin C in related conditions, this specific approach in sarcopenia is relatively novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

* probable sarcopenia defined according to EWGSOP2 criteria

Exclusion Criteria:

* Inability or unwillingness to provide informed consent;
* NH residents;
* schizophrenia or other psychotic disorders, bipolar syndrome;
* consumption of more than 14 alcoholic beverages per week;
* reduced cognitive performance (Mini-Mental State Examination score \<26);
* severe arthrosis;
* malignancies requiring treatment in the previous 3 years;
* lung disease requiring chronic corticosteroid therapy or oxygen therapy;
* severe cardiovascular disease;
* Parkinson's disease or other developmental neurological disorders;
* renal failure undergoing dialysis treatment;
* chest pain, severe dyspnea or conditions that may pose safety concerns when performing the 6-minute test or chair test;
* other medical, psychiatric or behavioral factors that, in the judgment of the researcher, may interfere with participation in the study;
* other illnesses related to an estimated life expectancy of less than 12 months.

Where this trial is running

Roma

• Fondazione Policlinico Universitario A. Gemelli IRCCS — Roma, Italy (RECRUITING)

Study contacts

• Principal investigator: Matteo Tosato — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Matteo Tosato

Conditions: Sarcopenia, aging, muscle wasting, physical function, handgrip, nitric oxide